Pallas Capital Advisors LLC Trims Stock Position in Zoetis Inc. $ZTS

Pallas Capital Advisors LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 84.7% during the fourth quarter, HoldingsChannel reports. The fund owned 2,385 shares of the company’s stock after selling 13,200 shares during the period. Pallas Capital Advisors LLC’s holdings in Zoetis were worth $300,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC increased its stake in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the last quarter. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis in the 4th quarter valued at $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the 3rd quarter worth $31,000. Holos Integrated Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter worth $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Zoetis during the 4th quarter worth about $38,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on ZTS. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. HSBC set a $140.00 price target on shares of Zoetis in a research report on Wednesday, December 10th. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday, December 18th. Finally, Barclays assumed coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Price Performance

ZTS opened at $117.45 on Thursday. The stock’s 50-day moving average price is $122.97 and its 200 day moving average price is $128.49. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a market cap of $49.58 billion, a price-to-earnings ratio of 19.51, a PEG ratio of 1.80 and a beta of 0.95.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.